Pharmaresearch Bio파마리서치바이오
217950 · KONEX · ₩217950 · 파마리서치바이오
₩29,250▲ ₩50 (0.17%)End-of-day · Oct 30, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩31B | ₩26B | ₩20B | ₩13B | ₩11B |
| Cost of sales | ₩9.3B | ₩9.3B | ₩7.7B | ₩5.7B | ₩5.2B |
| Gross profit | ₩22B | ₩17B | ₩12B | ₩6.8B | ₩5.3B |
| Operating income | ₩14B | ₩8.7B | ₩6.2B | ₩2.5B | ₩2.6B |
| Net income | ₩12B | ₩10B | ₩2.3B | ₩7.4B | ₩2.3B |
| Net income to shareholders | ₩12B | ₩10B | ₩2.3B | ₩7.4B | ₩2.3B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩105B | ₩87B | ₩64B | ₩59B | ₩50B |
| Current assets | ₩50B | ₩50B | ₩45B | ₩43B | ₩38B |
| Cash and equivalents | ₩8.7B | ₩35B | ₩10B | ₩9.2B | ₩8.9B |
| Total liabilities | ₩47B | ₩44B | ₩30B | ₩37B | ₩36B |
| Current liabilities | ₩46B | ₩43B | ₩28B | ₩20B | ₩23B |
| Borrowings | ₩34B | ₩31B | ₩21B | ₩20B | ₩16B |
| Total equity | ₩58B | ₩43B | ₩34B | ₩22B | ₩14B |
| Shareholders' equity | ₩58B | ₩43B | ₩34B | ₩22B | ₩14B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | ₩13B | ₩12B | ₩8.9B | ₩4.2B | ₩3.9B |
| Capital spending | ₩14B | ₩19B | ₩5.2B | ₩834M | ₩191M |
| Free cash flow | −₩730M | −₩7B | ₩3.6B | ₩3.4B | ₩3.7B |
Consolidated where available. Amounts in won.
Also known as: Pharmaresearch Bio / 파마리서치바이오 / 217950 / KRX:217950
Source: KRX statistical information